The use of denosumab (Xgeva) as an alternative to the more commonly prescribed zoledronic acid (Zometa) to slow down the development of bone metastases in men with advanced prostate cancer is becoming more common. The most common concern for men taking Zometa and now Xgeva has been osteonecrosis of the jaw. Osteonecrosis of the jaw [...]
Again, prostate cancer confusion continues to reign. A recent study reported at the ASTRO (American Society for Radiation Oncology) conference claims that the addition of androgen deprivation therapy (ADT) in men with clinically localized prostate cancer was not associated with increased cardiovascular mortality. According to Jason A. Efstathiou, MD, Ph.D.l, of the Massachusetts General Hospital [...]
We have just reached a red letter moment in the area of medical insurance. The provision of the Affordable Care Act that requires medical insurers to spend 80% of the consumers’ premium dollars they collect—85% for large group insurers—on actual medical care rather than overhead, marketing expenses and profit just kicked in to effect. This [...]
A recent article in the journal Cancer reported that there is an association for men being treated for prostate cancer with androgen deprivation therapy (ADT) and a risk of developing blood clots. The article, written by Edhaie et al. analyzed the Surveillance, Epidemiology and End Results (SEER) –Medicare database to identify 154,611 men over the [...]
Sometimes you have a good idea and you aren't sure why others don't get on board right away. It gets frustrating for some because they realize that the idea of "if you build it, they will come" does not hold up very well in reality. In fact what becomes more true is that if you [...]